Abstract
Covalent kinase inhibitors are receiving increasing attention as therapeutics with clinical benefits. A series of diaminopyrimidine derivatives incorporating reactive acrylamide warhead to covalently bind to cysteine 552 in FGFR4 were designed and synthesized. Among them, compound 5 h showed potent inhibitory activity against FGFR4 with an IC50 value of 0.1657 µM. Compounds 5 g and 5i demonstrated excellent antiproliferative activity against Huh-7 cells (IC50 = 10.09 μM) and Hep3B cells (IC50 = 7.58 μM), respectively. Molecular docking and MD simulations revealed the binding modes of compound 5 h within the ATP pocket and paved the way for further structural optimization as covalent FGFR4 inhibitors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
